- Home
- / NeonMind Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
NeonMind Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.2
2023-06-23
Market Capitalization
$425.1 K
2023-06-23
CreditSafe Score
?
Score changed on Jul 25, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 415.0K | 16.0K | |||||
| Cost of goods sold | 1.0K | 5.0K | |||||
| Gross profit | 414.0K | 11.0K | |||||
| Gross profit margin, % | 99.8% | 68.8% | |||||
| Operating expense total | 43.0K | 1.2M | 7.6M | 1.2M | 924.0K | 1.9M | 1.1M |
| Depreciation and amortization | 4.0K | 29.0K | 1.0K | ||||
| EBITDA | (43.0K) | (798.0K) | (7.5M) | (1.2M) | (3.0M) | (1.9M) | (1.1M) |
| EBITDA margin, % | -192.3% | -47143.7% | |||||
| EBIT | (43.0K) | (802.0K) | (7.0M) | (1.4M) | (3.1M) | (3.6M) | (1.1M) |
| EBIT margin, % | -193.3% | -43725.0% | |||||
| Interest expense | 25.0K | 33.0K | 101.0K | 100.0K | |||
| Pre tax profit | (1.4M) | (2.7M) | (7.2M) | (2.0M) | (3.1M) | (3.6M) | (1.5M) |
| Net Income | (1.4M) | (2.7M) | (7.2M) | (2.0M) | (3.1M) | (3.6M) | (1.5M) |